Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048961 | 0.90 | ABCB1 (0.69) | CA2CA9KDM4EABCB1ABCC1 | |
| SCHEMBL3042196 | 0.89 | DHCR7 (0.58) | CA2CA9KDM4EGAAMAPT | |
| SCHEMBL3064371 | 0.89 | CA9 (0.76) | CA2CA9KDM4EGAAMAPT | |
| SCHEMBL3061675 | 0.86 | REV1 (0.61) | CA2CA9KDM4EGAAMAPT | |
| SCHEMBL3056516 | 0.85 | KDM4E (0.66) | CA2CA9KDM4EGAAMAPT | |
| SCHEMBL3062059 | 0.84 | PDE4B (0.61) | CA2CA9KDM4EGAAMAPT | |
| SCHEMBL3055597 | 0.84 | REV1 (0.51) | CA2CA9KDM4EGAAMAPT | |
| SCHEMBL3049199 | 0.84 | REV1 (0.53) | CA2CA9KDM4EMAPTABCB1 | |
| SCHEMBL3045905 | 0.84 | KDM4E (0.52) | CA2CA9KDM4EMAPTABCB1 | |
| SCHEMBL3061514 | 0.83 | CA2 (0.49) | CA2CA9KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | claimed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | claimed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2155192-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | Sterix Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117061-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | CA2 1077/4885CA9 1002/4885KDM4E 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.